anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain saiko saponin having a hepatic damage-improving action, etc., useful as a galenical ingredient, etc., in a short time in a largely increased yield by culturing the tissue-cultured root of a plant belonging to the genus Bupleurum in a culture medium containing an organic acid salt. CONSTITUTION: A method for producing siaiko saponin comprises wrapping the seed of a Bupleurum plant (e.g. Bupleurum falcatum) with a gauze, immersing the wrapped seed in 70% ethanol for 10sec. rinsing the wrapped seed with water, treating the rinsed seed with a 2% antiformin solution for 10min, immersing the treated seed in sterilized water at room temperature over a night, planting the treated seed in a culture medium, culturing and germinating the seed at 22 deg.C periodically alternately in a dark place and in a lighted place, subculturing the germinated seedling at 26 deg.C in a medium containing 3% sucrose at 26 deg.C for 12hr, cutting the roots, etc., of the aseptically grown plant, culturing the cut roots in a culture medium containing indolebutyric acid, culturing the generated callus and roots in a medium containing an organic acid salt (e.g.  sodium acetate), lyophilizing the cultured product, grinding the lyophilized product with a mixer, and finally extracting the ground product with 75% ethanol containing 0.5% KOH. Thus, the objective saiko saponin is obtained in a high yield.
Advances in cancer treatment are producing a growing number of cancer survivors; therefore, issues surrounding quality of life during and following cancer treatment have become increasingly important. Chemotherapy-related cognitive impairment (CRCI) is one such quality of life issue that is commonly reported following chemotherapy treatment in adults. Although studies reporting cognitive impairments associated with chemotherapy have been reported since the 1980s, the phenomenon commonly referred to as 'chemo brain' or 'chemo fog' is poorly understood, and for some patients becomes the most distressful survivorship issue faced. Studies suggest that while up to up to 75% exhibit cognitive decline during treatment, many patients will return to their pre-chemo level of functioning 1 year after completing treatment. However, for 30-35% of cancer patients, their cognitive issues persist.

Studies suggest that this persistent chemotherapy-related cognitive impairment (pCRCI) can remain for months to years after completing treatment, which may have implications for the trajectory of how both normal cognitive aging occurs, but also the risk of cognitive disorders such as Alzheimer's disease, for the growing number of long-term cancer survivors. These concerns are particularly relevant for older individuals as risk for not only cancer, but cognitive impairment (such as dementia) increases with age. As of January 2016, 62% of cancer survivors (9.61 million) are currently 65 years or older, and this number is expected to increase dramatically over the coming decades. Therefore, as the number of older cancer survivors who have will have to cope with pCRCI is likely to increase, it is crucial that The investigators understand the cognitive impairments, the impact on survivors' functioning, and develop treatments for pCRCI.

The investigators propose to target cognitive deficit in CRCI using a novel cognitive enhancement strategy. Our choice of cognitive focus is informed by clinical, behavioral and neurobiological data suggesting a reliable association between cognitive control deficits (CCD), damage to the cognitive control network (CCN), and decline in cognitive functioning. The CCN is a neural network that supports important cognitive control functions such as alerting and orienting attention, response selection, cognitive flexibility, strategy generation, and inhibition of prepotent responses. The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to the treatment of CRCI as it has demonstrated training and transfer effects of enhanced CCN function in a similar, abnormally aging population. The theory guiding neuroplasticity-based cognitive interventions is that network abnormalities associated with negative disease-specific clinical outcomes can be altered through the induction of neuroplasticity (even in the aging brain) resulting in enhanced functioning of the target network, and symptomatic improvements.
Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase) and in addition receive navigated retinal laser photocoagulation at M3. Patients will receive aflibercept according to pro re nata regimen from M3-M12.
In patients with type 1 diabetes mellitus, empagliflozin, a component of SYNJARDY or SYNJARDY XR, significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond the background rate. In placebo-controlled trials of patients with type 1 diabetes mellitus, the risk of ketoacidosis was markedly increased in patients who received sodium glucose co-transporter 2 (SGLT2) inhibitors compared to patients who received placebo and fatal ketoacidosis has occurred with empagliflozin. SYNJARDY and SYNJARDY XR are not indicated for glycemic control in patients with type 1 diabetes mellitus.

Type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are also risk factors for ketoacidosis. There have been postmarketing reports of fatal events of ketoacidosis in patients with type 2 diabetes mellitus using SGLT2 inhibitors, including SYNJARDY or SYNJARDY XR.

Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse.

Signs and symptoms are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. Blood glucose levels at presentation may be below those typically expected for diabetic ketoacidosis (e.g., less than 250 mg/dL). Ketoacidosis and glucosuria may persist longer than typically expected. Urinary glucose excretion persists for 3 days after discontinuing SYNJARDY or SYNJARDY XR [see Clinical Pharmacology (12.2)]; however, there have been postmarketing reports of ketoacidosis and/or glucosuria lasting greater than 6 days and some up to 2 weeks after discontinuation of SGLT2 inhibitors.

Consider ketone monitoring in patients at risk for ketoacidosis if indicated by the clinical situation. Assess for ketoacidosis regardless of presenting blood glucose levels in patients who present with signs and symptoms consistent with severe metabolic acidosis. If ketoacidosis is suspected, discontinue SYNJARDY or SYNJARDY XR, promptly evaluate, and treat ketoacidosis, if confirmed. Monitor patients for resolution of ketoacidosis before restarting SYNJARDY or SYNJARDY XR.

Withhold SYNJARDY or SYNJARDY XR, if possible, in temporary clinical situations that could predispose patients to ketoacidosis. Resume SYNJARDY or SYNJARDY XR when the patient is clinically stable and has resumed oral intake [see Dosage and Administration (2.6)].

Educate all patients on the signs and symptoms of ketoacidosis and instruct patients to discontinue SYNJARDY or SYNJARDY XR and seek medical attention immediately if signs and symptoms occur.
<P>PROBLEM TO BE SOLVED: To make an enzyme and an enteric substance to arrive at an intestine without being exposed to a gastric juice.  <P>SOLUTION: An oil liquid 2 containing CoQ<SB>10</SB>of enteric substance is encapsulated with a gelatin coating film 3 to form a seamless nucleus 1, and an enzyme-containing coating film 4 is disposed on the surface of the seamless nucleus 1 to form an enzyme-compounded granule 5. The enzyme-compounded granules 5 are charged and sealed in a hard capsule 6, and the whole surface of the capsule is coated with zein 7 to form an enzyme-compounded food 8. When the enzyme-compounded food 8 is drunk, the enzyme-compounded food 8 arrives at the intestine through a stomach without being dissolved in a gastric juice due to the existence of the coating layer of the zein 7. The coating layer of the zein 7, and the hard capsule 6 are sequentially collapsed in the intestine, and the enzyme compounded in the enzyme-containing coating films 4 of the enzyme-compounded granules 5 are released in the intestine. The gelatin coating films 3 of the seamless nuclei 1 exposed by the collapse of the coating films 4 are collapsed to release the oil liquid 2 containing the CoQ<SB>10</SB>in the intestine.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a dermal preparation for external use, capable of improving a rough skin and excellent in beautiful skin maintaining effect by blending a specific compound having a humidity maintaining effect and an activity of preventing a stratum corneum from a stratification with a saikosaponin extracted from a plant such as Buplenri radix. SOLUTION: This dermal preparation for external use is prepared by concurrent use of a saikosaponin with a low molecular weight betaine. As the saikosaponin, saikosaponin b1 and/or saikosaponin b2 are preferable. As the low molecular weight betaine, a quaternary ammonium salt of the formula [R<1> to R<3> are each a 1-6C alkyl; (n) is 0 or positive integer, provided that the total of the total carbon number in R<1> to R<3> and (n), is <=8] is preferable. The saikosaponin is blended by 0.0001-20wt.%, especially 0.001-10wt.% based on the total amount of the dermal preparation for external use. The low molecular weight betaine is blended by 0.01-30wt.%, especially 0.1-20wt.% based on the total amount of the dermal preparation for external use.  Since this dermal preparation for external use has the excellent effects of preventing and improving skin roughness by a synergistic effect, and also humidity maintaining effect, the beautiful skin maintaining effect is obtained, and also powdery feeling in its use is suppressed.
The present invention provides a double-layer capsule structure and a preparation method thereof. The double-layer capsule having a malleable capsule and a non-malleable capsule manufactured by imitating the structure of an egg having an outer shell and an inner membrane. The malleable capsule of the double-layer capsule is provided with a first accommodating space and a first filler. The first filler is disposed in the first accommodating space. The non-malleable capsule is disposed outside the malleable capsule and is provided with a second accommodating space and a second filler. The malleable capsule contains a thickener and a first gelatin in a weight ratio of 1:0.5 to 1:1.5. The non-malleable capsule contains a flour and a second gelatin in a weight ratio of 1:0.5 to 1:1.5.
Exercise is known to induce changes in brain neuroplasticity in the elderly and is thought to have a protective effect against cognitive decline in patients already suffering from neurodegenerative diseases. While the benefits of exercise in the context of mild cognitive impairment and Alzheimer's disease have been extensively studied, little information is available on the potential benefits of exercise for other atypical neurodegenerative diseases, such as primary progressive aphasia (PPA). A multimodal exercise intervention (combination of aerobic and resistance exercises) could potentially slow overall cognitive decline in PPA, which is characterized by a gradual and isolated dissolution of language function, by promoting neurogenesis and neuroplasticity. In healthy but inactive older adults, exercise increases grey and white matter volume in prefrontal and temporal cortical regions, which are specifically impaired in PPA and play an important role in executive functions, episodic memory and language skills. Exercise could thus modulate certain executive, memory and language difficulties generally observed in this clinical population. This pilot study aims to evaluate the feasibility of a novel home-based multicomponent exercise program in adults clinically diagnosed with any of the three main variants of PPA (semantic, non-fluent/agrammatic or logopenic). The feasibility outcomes will be based on: 1) total recruitment and recruitment rate, 2) program completion rate, 3) compliance and 4) participants' ability to train at home with or without a caregivers' presence. A minimum of 12 participants will be recruited through McGill University's Douglas Research Institute and will complete a 6-month home-based multimodal intervention program. They will train two to three times a week for 45 minutes and be supervised via videoconference by a kinesiologist from the EPIC Center at the Montreal Heart Institute. If desired, participants will be accompanied by a partner, close friend, or relative to facilitate communication, especially if they have difficulty understanding instructions or expressing themselves. To assess changes in cognition, physical and psychological functions, participants will complete neuropsychological and functional assessments in-person at baseline. These assessments will also be completed at three and six months post-intervention. The knowledge gained from this pilot project will be used to assess the feasibility of a full randomized control trial aimed at assessing the effects of multimodal exercise intervention in PPA patients. Ultimately, an increased understanding of the potential beneficial effects of physical exercise in PPA will allow for more tailored rehabilitative approaches in this clinical population.
Methods and devices for molecular imprinting include a molecular imprinting synthesis and matching a physiological pH of a template utilized in the molecular imprinting synthesis to achieve molecular imprinting. Molecular imprinting can be achieved by matching the physiological pH of the template used in a molecular imprinting synthesis. Furthermore, electrostatic charges can be complementary matched to the template, by obtaining crystallographic data of a protein template. Particularly, positively and negatively charged amino acids can be counted and matched by an oppositely charged monomer. For hydrophobic amino acids, isoleucin, leucin, and valine amino acids are counted. Since not all hydrophobic amino acids are exposed, the hydrophobic amino acid and hydrophobic monomer ratio can be determined experimentally by varying ratios from 1:1 to 1:10.
Mold growth on body donations remains an underreported yet serious issue in anatomical teaching. Bacterial and fungal growth pose health risks to lecturers and students, alongside with ethical and aesthetic concerns. However, limited information exists on the presence of bacteria and fungi on body donations and their underlying causes. To investigate the potential impact of airborne germs on body donation contamination, we conducted indoor air measurements before, during, and after our anatomical dissection course, with outdoor measurements serving as a control. Tissue samples from the dissected body donations were collected to assess the germ load, with qualitative and quantitative microbiological analyses. Air samples from the dissection hall contained no fungi, but various fungal species were identified in the adjacent stairways and outdoors which implies that fungal occurrence in the dissection hall air was independent of lecturers' and students' presence. Moreover, our results indicate that adequate ventilation filters can effectively reduce indoor fungal germs during courses, while the bacterial load in room air appears to increase, likely due to the presence of lecturers and students. Additionally, the tissue samples revealed no bacterial or fungal germs which implies that our ethanol-formalin-based embalming solution demonstrates an effective long-term antimicrobial preservation of corpses.
Deaf patients who communicate in American Sign Language (ASL) experience communication challenges leading to medical errors, treatment delays, and health disparities. Research on Deaf patient communication preferences is sparse. Researchers conducted focus groups based on the Health Belief Model with culturally Deaf patients and interpreters. The ASL focus groups were interpreted and transcribed into written English, verified by a third-party interpreting agency, and uploaded into NVivo. Deductive coding was used to identify communication methods and inductive coding was used to identify themes within each. Writing back-and-forth introduced challenges related to English proficiency, medical terminology, poor penmanship, and tendencies of providers to abbreviate. Participants had various speechreading abilities and described challenges with mask mandates. Multiple issues were identified with family and friends as proxy interpreters, including a lack of training, confidentiality issues, emotional support, and patient autonomy. Video remote interpreter challenges included technical, environmental, and interpreter qualification concerns. Participants overwhelmingly preferred on-site interpreters for communication clarity. While there was a preference for direct care, many acknowledged this is not always feasible due to lack of providers fluent in ASL. Access to on-site interpreters is vital for many Deaf patients to provide full access to critical medical information. Budget allocation for on-call interpreters is important in emergency settings.
Detecting genetic variants enables risk factor identification, disease screening, and initiation of preventative therapeutics. However, current methods, relying on hybridization or sequencing, are unsuitable for point-of-care settings. In contrast, CRISPR-based-diagnostics offer high sensitivity and specificity for point-of-care applications. While these methods have predominantly been used for pathogen sensing, their utilization for genotyping is limited. Here, we report a multiplexed CRISPR-based genotyping assay using LwaCas13a, PsmCas13b, and LbaCas12a, enabling the simultaneous detection of six genotypes. We applied this assay to identify genetic variants in the APOL1 gene prevalent among African Americans, which are associated with an 8-30-fold increase in the risk of developing kidney disease. Machine learning facilitated robust analysis across a multicenter clinical cohort of more than 100 patients, accurately identifying their genotypes. In addition, we optimized the readout using a multi-analyte lateral-flow assay demonstrating the ability for simplified genotype determination of clinical samples. Our CRISPR-based genotyping assay enables cost-effective point-of-care genetic variant detection due to its simplicity, versatility, and fast readout.
PURPOSE: To obtain a medicine composition for parenteral administration, containing navelbine, prepared in the form of a stable injection solution capable of being immediately used. CONSTITUTION: This medicine composition contains a water-soluble navelbine salt (e.g. the ditartarate salt), an osmotic pressure-adjusting agent, an antibacterial preservative, and distilled water for injection. The osmotic pressure-adjusting agent is selected from electrolytes such as sodium chloride, amino acids such as glycine, saccharides such as glucose, and/or polyols such as mannitol. The antibacterial preservative is selected from p-hydroxybenzoic acid and its salt, benzyl alcohol, mercury-containing compounds, chlorobutanol, and phenol derivatives. The water-soluble salt of the navelbine is used at a dose of 10-50mg as the amount of free navelbine base.
INTRODUCTION: GINS2 exerts a carcinogenic effect in multiple human malignancies, while it is still unclear that the potential roles and underlying mechanisms of GINS2 in HNSCC.
METHODS: TCGA database was used to screen out genes with significant differences in expression in HNSCC. Immunohistochemistry and qRT-PCR were used to measure the expression of GINS2 in HNSCC tissues and cells. GINS2 was detected by qRT-PCR or western blot after knockdown or overexpression. Celigo cell counting, MTT, colony formation, and flow cytometric assay were used to check the ability of proliferation and apoptosis. Bioinformatics and microarray were used to screen out the downstream genes of GINS2.
RESULTS: GINS2 in HNSCC tissues and cells was up-regulated, which was correlated with poor prognosis. GINS2 gene expression was successfully inhibited and overexpressed in HNSCC cells. Knockdown of GINS2 could inhibit proliferation and increase apoptosis of cells. Meanwhile, overexpression of GINS2 could enhance cell proliferation and colony formation. Knockdown of RRM2 may inhibit HNSCC cell proliferation, while overexpression of RRM2 rescued the effect of reducing GINS2 expression.
CONCLUSION: Our study reported the role of GINS2 in HNSCC for the first time. The results demonstrated that in HNSCC cells, GINS2 promoted proliferation and inhibited apoptosis via altering RRM2 expression. Therefore, GINS2 might play a carcinogen in HNSCC, and become a specific promising therapeutic target.
The invention belongs to microbial medicine field, it relates to a kind of bacterial strain and application thereof producing herbimycin, is this bacterial strain through morphological specificity, cultural characteristic, physiological and biochemical property and 16S? rDNA genetic analysis, identify its be a strain streptomyces hygroscopicus (<i>streptomyces? hygroscopicus</i>). Register on December 6th, 2013 in China General Microbiological culture presevation administrative center, deposit number: CGMCC? No.8544. In this bacterium fermented supernatant fluid after activeconstituents organic solvent extraction, through ultra-violet absorption spectrum, infrared absorption spectrum, NMR (Nuclear Magnetic Resonance) spectrum and mass spectrometric detection analysis, confirm that its activeconstituents is Herbimycin? A(Antibiotic TAN 420F), belong to benzoquinones Ansamycin, fermentation level can reach 1500 more than �� g/mL, it may be achieved industrialization, and it is convenient to extract, component is single, good product quality. Herbimycin? A has important biologic activity, can be used as organ transplantation anti-rejection drugs, has broad-spectrum weed-killing activity, has faint antibacterium and anti-mycotic activity. In addition, Herbimycin? A is inhibited to kinds of tumor cells.
Frailty relates to the concept of physical deterioration associated with the aging process, which includes a weakening of the physiological and integrated physical strength of the body, its reserve and resistance to stressors, resulting in poor health, such as loss of physical and mental performance. Frailty is an important health care topic in patients with geriatric syndromes. Once the elderly enter the early stage of frailty, they are likely to fall repeatedly. Studies have shown that frailty and premature aging are important predictors of falls in the elderly. Therefore, professional medical staff should use frailty assessment indicators as early as possible to assess the possibility of frailty among the elderly in medical institutions or communities. At the same time, effective prevention strategies should be adopted to prevent reduce the incidence of falls due to frailty and improve the quality of life of patients and the elderly. Therefore, assessment of possible falls and frailty risks is a priority in acute care settings.